Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start. 

The newly approved device is much smaller than previous offerings, helping operators capture 3D images during structural heart evaluations. 

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Jeremy Slivnick, MD, spoke with Cardiovascular Business about AI's potential to transform how cardiac amyloidosis is diagnosed and treated. 

Injuries to the esophagus remain a common complication associated with radiofrequency ablation procedures. New research suggests a device developed by S4 Medical could significantly reduce the risk of such injuries. 

The device, which also received Great Britain’s UKCA marking, was specifically designed to be less bulky and easier to wear than other wearable cardioverter-defibrillators.

Researchers tracked data from more than 500 PCI patients, exploring the cost-effectiveness and safety of multiple treatment options. 

For this update to be finalized, the American Medical Association had to determine FFR_CT Analysis met certain requirements in terms of its overall impact on patient care. John Farquhar, CEO of HeartFlow, described the news as "a win for everyone involved, most notably patients."